GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
HAMPTON, N.J., Sept. 22, 2017 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017 at 11:30 a.m. EDT in New York.
The live webcast will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
(781) 433-3161
[email protected]
Charles Liles
Associate Director, Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(617) 383-3433
[email protected]
